Blend is developing novel cancer therapeutics designed to overcome efficacy barriers for improved targeting of cancer.
Innovative cancer therapies that target solid tumor biology. We create novel cancer drugs designed to address the challenges that limit the efficacy and tolerability of cancer drugs in use today, which include: targeting of cancer cells selectively, sufficiently accumulating drug at the site of the tumor, achieving potent cell-killing activity with patient tolerability, and penetrating throughout the cells in dense tumor tissue.
Blend’s innovative medicines are based on a proprietary suite of miniaturized biologic drug conjugate (mBDC) and nanoparticle technologies. Our skilled and inventive approach to cancer drug development is evident in two distinct advances in cancer therapeutics:
- The Pentarin platform is centered around Blend’s novel, miniaturized biologic drug conjugates (mBDCs). These mBDCs are comprised of a proprietary targeting ligand linked to a potent cell-killing agent, with the additional therapeutic features conferred by incorporation into polymeric nanoparticles. The result is a product engine enabling us to develop novel drug conjugates with unprecedented ability to therapeutically penetrate deep inside the tumor tissue and specifically target tumor cells. In our R&D process we optimize these properties for superior efficacy in fighting cancer. Blend’s first Pentarin drug candidate is BTP-277, which is planned for clinical trials in early 2016 for selected subpopulations of patients with small-cell lung and neuroendocrine cancers.
- A novel personalized Platinum therapeutic, BTP-114, is Blend’s lead clinical candidate. This novel therapeutic was discovered by Blend’s R&D team including the expertise of the company’s founder, Professor Stephen Lippard, in platinum chemistry. A new chemical entity, BTP-114 is a novel personalized cisplatin prodrug designed with the modern insights from cancer biology, genomics and targeting. Once administered, BTP-114 rapidly conjugates to serum albumin in blood with a high degree of specificity, and is preferentially taken up by cancer cells with certain molecular profiles, resulting in enhanced DNA damage and cell death.
Blend is rapidly developing its pipeline of innovative cancer therapeutics. With the Pentarin platform, we are developing an internal pipeline of proprietary drug conjugates, and the platform also serves as the foundation for developing Pentarins to enhance the therapeutic capabilities of the targeting protein scaffolds or payloads of pharmaceutical collaborators.
Blend was founded by three leaders in the fields of nanomedicine and chemistry from the Brigham and Women’s Hospital (BWH)–Harvard Medical School (HMS), and Massachusetts Institute of Technology (MIT): Dr. Omid Farokhzad of BWH–HMS, and Dr. Robert Langer and Dr. Stephen J. Lippard of MIT. The company has attracted top-tier investors including Flagship Ventures, NanoDimension and New Enterprise Associates.